Evotec Achieves Milestone in an Ion Channel Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.

6/27/2011, 7:31 AM (Source: GlobeNewswire)
Evotec AG /
Evotec Achieves Milestone in an Ion Channel Drug Discovery Collaboration with
Ono Pharmaceutical Co., Ltd.
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

* Evotec receives  a milestone payment from Ono for the progression of novel
ion channel modulators into lead optimization

Hamburg, Germany -27 June 2011: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced the achievement of specific success criteria in an ion
channel research collaboration with Ono Pharmaceutical Co., Ltd. (Ono) and the
receipt of a milestone payment. This collaboration project was initiated in
October 2009 to identify small molecules targeting an ion channel implicated in
cardiovascular, CNS and urological diseases in one and a half years and now
successfully identified multiple compounds meeting various criteria in activity,
selectivity and pharmacokinetic characteristics. Evotec and Ono now agree to
continue this research collaboration until April 2012 and enter into lead
optimisation with the goal to generate new chemical entities, which will have
the potential to become new drug candidates. Ono has a worldwide right to
develop and commercialize compounds generated by Evotec in this collaboration.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are
delighted to deliver high value molecules to our partner Ono and to expand our
collaboration. We enjoy a very successful and close relationship. This
achievement clearly demonstrates the value we bring to our alliance partners in
the area of drug discovery. We look forward to continuing working closely with
our colleagues at Ono."

"We are very pleased to achieve the research milestone and progress into lead
optimisation with a project. We highly appreciate a wide range of drug discovery
technologies at Evotec and the experiences of their scientists. We are confident
that multiple preclinical candidates will be identified in near future" said
Kazuhito Kawabata, Ph.D., Managing Director, Research Headquarters at Ono.

Contact: Dr  Werner Lanthaler, Chief Executive Officer, Evotec AG, Phone:
+49.(0)40.56081-242, werner.lanthaler@evotec.com

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions or
circumstances on which any such statement is based.

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

PDF of press release:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.